Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

Phase 3

2(33.3%)

Phase 1

1(16.7%)

N/A

1(16.7%)

6Total

Phase 2(2)

Phase 3(2)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05653063Recruiting

ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

Role: collaborator

NCT00041210Phase 3Unknown

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma

Role: lead

NCT00003747Phase 1Unknown

Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma

Role: lead

NCT00033436Phase 3Completed

Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer

Role: lead

NCT00873236Phase 2Unknown

MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer

Role: lead

NCT00305838Phase 2Unknown

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

Role: lead

NCT00828516Not ApplicableCompleted

Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema

Role: collaborator

All 7 trials loaded